Scientific Committee

  • Judith Aldridge (Senior Lecturer, School of Law, University of Manchester, UK)
  • Alexander Baldacchino (Professor of Medicine, Psychiatry and Addictions, University of St Andrews, UK)
  • Henri Bergeron (Chair in Health Studies, Sciences Po Paris, France)
  • Virginia Berridge (Professor of History and Director, Centre for History in Public Health, London School of Hygiene and Tropical Medicine, UK)
  • Kim Bloomfield (Professor, Center for Alcohol and Drug Research, Aarhus University, Denmark)
  • Henrietta Bowden-Jones (Consultant Psychiatrist. Founder and Director, National Problem Gambling Clinic, UK)
  • Jørgen G. Bramness (Senior researcher, Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Norwegian Centre of Dual Diagnosis)
  • Anne Line Bretteville-Jensen (Research Director, Norwegian Institute for Alcohol and Drug Research (SIRUS), Norway)
  • Angelina Brotherhood (Public Health Researcher, Liverpool John Moores University, UK)
  • Rachel Btaiche (Focal Person, National Observatory on Drugs and Drug Addiction, Ministry of Public Health, Lebanon)
  • Gerhard Bühringer (Chair of Addiction Research, Institute for Clinical Psychology and Psychotherapy, Technische Universität Dresden, Germany)
  • Catherine Comiskey (Head of School of Nursing and Midwifery, Trinity College, Ireland)
  • Ornella Corazza (Reader in Substance Addictions and Behaviours, University of Hertfordshire, Hatfield, UK)
  • Paul Dargan (Consultant Physician and Clinical Toxicologist, Guy's and St Thomas' NHS Foundation Trust, and Reader in Toxicology, King’s College London, UK)
  • Marina Davoli (Head, Department of Epidemiology, National Agency for Health Services, Italy)
  • Louisa Degenhardt (Professor, National Drug and Alcohol Research Centre (NDARC), Australia)
  • Zsolt Demetrovics (ELTE Eötvös Loránd University, Budapest, Hungary)
  • Cuneyt Evren (Associate Professor of Psychiatry, Head of Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM), Istanbul, Turkey)
  • Fernando Rodríguez de Fonseca (Fundación IMABIS, Hosp. Univ. Carlos Haya de Málaga, Spain)
  • Fabrizio Faggiano (Professor of Public Health at the Department of Translational Medicine of the University of the Piemonte Orientale, Italy)
  • Michael Farrell (Director, National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Australia)
  • Gabriele Fischer (Medical Director of the Addiction Clinic at the Medical University Vienna, Austria)
  • Henk Garretsen (Professor, Director Tranzo, Scientific Centre for Care and Welfare, Tilburg University, The Netherlands)
  • Eilish Gilvarry (President of the Society for the Study of Addiction, Honorary Professor of Addiction Psychiatry, Newcastle University, UK)
  • Manuela Grazina (Professor, Faculty of Medicine; Researcher and Head of Laboratory of Biochemical Genetics, Center for Neuroscience and Cell Biology; University of Coimbra, Portugal)
  • Jason Grebely (Associate Professor, The Kirby Institute, UNSW Sydney, Australia)
  • Antoni Gual (Director of the Addictions Unit, Hospital Clínic Barcelona, Spain)
  • Wayne Hall (Professor, Director and Inaugural Chair, Centre for Youth Substance Abuse Research, The University of Queensland, Australia)
  • Matthew Hickman (School of Social and Community Medicine, University of Bristol, UK)
  • Susana Jiménez-Murcia (Head of Pathological Gambling Unit, Department of Psychiatry, University Hospital of Bellvitge, Barcelona, Spain)
  • Beau Kilmer (Co-director and senior policy researcher, RAND Drug Policy Research Center; Professor, Pardee RAND Graduate School, USA)
  • Dirk Korf (Professor, Bonger Institute of Criminology, University of Amsterdam, The Netherlands)
  • Krzysztof Krajewski (Chair of Criminology, Jagiellonian University, Poland)
  • Ludwig Kraus (Director, IFT Institut für Therapieforschung, Munich, Germany)
  • Håkan Leifman (Director, Swedish Council for Information on Alcohol and Other Drugs (CAN), Sweden)
  • Henrique Lopes (Scientific coordinator of the Public Healthcare Unit of the Portuguese Catholic University / President of the Ibero-latin-american Scientific Society SOCILEJ / President of the Sectorial Commission for Health Quality)
  • Pia Mäkelä (Head of Alcohol and Drugs Unit, National Institute for Health and Welfare, Finland)
  • Meni Malliori (Professor of Psychiatry, Eginition Hospital, National & Kapodistrian University of Athens, Greece)
  • Angela Me (Chief of the Research and and Trend Analysis Branch, United Nations Office on Drugs and Crime)
  • Emília Nunes (Professor, Director of the National Programme for Prevention of Smoking and Tobacco Control, General-Directorate of Health, Portugal)
  • Letizia Paoli (Professor, Leuven Institute of Criminology, University of Leuven, Faculty of Law, Belgium)
  • Amy Porath (Director, Research and Policy, Canadian Centre on Substance Abuse, Canada)
  • Jürgen Rehm (Director, Social and Epidemiological Research (SER) Department, Centre for Addiction and Mental Health, Toronto, Canada)
  • Xavier Majó i Roca (Office of Drug Addiction, Public Health Agency of Catalonia, Spain)
  • Tim Rhodes (Professor of Public Health Sociology, London School of Hygiene and Tropical Medicine (UK)/University of New South Wales (Australia))
  • Zila M. Sanchez (Professor of Epidemiology, Preventive Medicine Department, Universidade Federal de São Paulo, Brazil)
  • Emanuele Scafato (Director of Population’s Health and Health Determinants Unit in the National Centre for Epidemiology, Surveillance and Health Promotion-CNESPS at the Istituto Superiore di Sanità, Italy)
  • Eberhard Schatz (Coordinator CORRELATION network)
  • Janusz Sieroslawski (Institute of Psychiatry and Neurology, Poland)
  • Zili Sloboda (President, Applied Prevention Science, Inc., USA)
  • Rainer Spanagel (Professor of Pharmacology & Toxicology, Head of the Institute of Psychopharmacology, University of Heidelberg, Germany)
  • Kerstin Stenius (Assistant Professor, Centre for Social Research on Alcohol and Drugs, Stockholm University, Sweden; Alcohol and Drugs unit, National Institute for Health and Welfare, Finland; and Nordic Centre for Welfare and Social Issues, Finland)
  • John Strang (Professor, Head of the Addictions Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, UK)
  • Harry Sumnall (Professor, Centre for Public Health, Liverpool John Moores University, UK)
  • Margriet Van Laar (Head of the Department Drug Monitoring, Trimbos Institute, The Netherlands)
  • Julian Vicente (Lead scientist, epidemiology, EMCDDA)
  • Graça Vilar (Director of the Planning and Intervention Department of SICAD, Master in forensic medicine and forensic sciences, Graduate Assistant of Psychiatry Hospital, Portugal)
  • Chris Wilkins (Senior Researcher, Drugs Team Leader, SHORE & Whariki Research Centre, College of Health, Massey University, Auckland, New Zealand)

Categories:

  • Committee